Insmed Q2 2026 revenue $425.5M; BRINSUPRI $309.2M; raises FY guidance to $1.25-1.40B

INSMED Inc

2026-Q2 EPS reported -$0.82 revenue$731,450,000

Total Q2 2026 revenue $425.5M, up 296% YoY; BRINSUPRI $309.2M (49% QoQ growth), ARIKAYCE $116.3M (+8% YoY).
Net loss narrowed to $13.2M ($0.06/sh) from $321.7M ($1.70/sh) in Q2 2025; cash & securities $1.2B.
Raised 2026 BRINSUPRI revenue guidance to $1.25B-$1.40B (from at least $1B); ARIKAYCE guidance reiterated at $450M-$470M.
Raised peak revenue estimate for BRINSUPRI to >$7B, TPIP to >$6B, total three lead programs >$14B.
Submitted sNDA for ARIKAYCE in newly diagnosed MAC lung disease; positive 12-month TPIP OLE data in PAH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.